AARTIDRUGSPharmaceuticals
Aarti Drugs Ltd — Cash Flow Statement
₹319.75
-3.05%
Aarti Drugs Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 67.42 Cr | 132.59 Cr | -31.50 Cr | -81.56 Cr | — |
| Repurchase Of Capital Stock | -59.85 Cr | -59.85 Cr | 0.00 | -60.00 Cr | — |
| Repayment Of Debt | -77.61 Cr | -45.94 Cr | -55.86 Cr | -6.87 Cr | — |
| Issuance Of Debt | 70.24 Cr | 148.19 Cr | 115.84 Cr | 202.82 Cr | — |
| Capital Expenditure | -177.16 Cr | -226.33 Cr | -164.82 Cr | -151.97 Cr | — |
| End Cash Position | 4.58 Cr | 6.74 Cr | 7.50 Cr | 21.61 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 0.01 Cr | — | — | -1000.00 | — |
| Beginning Cash Position | 6.74 Cr | 7.50 Cr | 21.61 Cr | 8.81 Cr | — |
| Changes In Cash | -2.17 Cr | -0.76 Cr | -14.11 Cr | 12.80 Cr | — |
| Financing Cash Flow | -82.12 Cr | -136.03 Cr | 16.54 Cr | 92.03 Cr | — |
| Net Other Financing Charges | -13.32 Cr | -13.32 Cr | 1000.00 | -13.84 Cr | — |
| Interest Paid Cff | -33.44 Cr | -31.31 Cr | -36.19 Cr | -20.58 Cr | — |
| Cash Dividends Paid | -9.06 Cr | -9.27 Cr | -9.40 Cr | -9.51 Cr | — |
| Net Common Stock Issuance | -59.85 Cr | -59.85 Cr | 0.76 Cr | -60.00 Cr | — |
| Common Stock Payments | -59.85 Cr | -59.85 Cr | 0.00 | -60.00 Cr | — |
| Net Issuance Payments Of Debt | 33.55 Cr | -22.28 Cr | 61.37 Cr | 195.95 Cr | — |
| Net Short Term Debt Issuance | 40.92 Cr | -124.53 Cr | 1.40 Cr | — | — |
| Net Long Term Debt Issuance | -7.37 Cr | 102.25 Cr | 59.98 Cr | 195.95 Cr | — |
| Long Term Debt Payments | -77.61 Cr | -45.94 Cr | -55.86 Cr | -6.87 Cr | — |
| Long Term Debt Issuance | 70.24 Cr | 148.19 Cr | 115.84 Cr | 202.82 Cr | — |
| Investing Cash Flow | -164.63 Cr | -223.65 Cr | -163.97 Cr | -149.64 Cr | — |
| Interest Received Cfi | 12.20 Cr | 2.50 Cr | 0.70 Cr | 0.72 Cr | — |
| Dividends Received Cfi | 0.01 Cr | 0.00 | 11000.00 | 1.60 Cr | — |
| Net Investment Purchase And Sale | 0.27 Cr | 0.00 | 0.00 | 0.00 | — |
| Sale Of Investment | 0.27 Cr | 0.00 | — | — | 0.00 |
| Purchase Of Investment | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -177.11 Cr | -226.14 Cr | -164.67 Cr | -151.95 Cr | — |
| Sale Of PPE | 0.05 Cr | 0.19 Cr | 0.15 Cr | 0.02 Cr | — |
| Purchase Of PPE | -177.16 Cr | -226.33 Cr | -164.82 Cr | -151.97 Cr | — |
| Operating Cash Flow | 244.58 Cr | 358.92 Cr | 133.32 Cr | 70.41 Cr | — |
| Taxes Refund Paid | -55.12 Cr | -62.40 Cr | -59.67 Cr | -83.38 Cr | — |
| Change In Working Capital | 3.58 Cr | 102.79 Cr | -116.34 Cr | -187.35 Cr | — |
| Change In Payable | -43.73 Cr | -92.53 Cr | -27.74 Cr | 117.15 Cr | — |
| Change In Inventory | 12.96 Cr | 34.25 Cr | 5.82 Cr | -110.63 Cr | — |
| Change In Receivables | 34.35 Cr | 161.07 Cr | -94.42 Cr | -193.87 Cr | — |
| Other Non Cash Items | 23.67 Cr | 31.02 Cr | 35.49 Cr | 19.86 Cr | — |
| Provisionand Write Offof Assets | 3.72 Cr | 1.90 Cr | 0.76 Cr | 1.69 Cr | — |
| Depreciation And Amortization | 55.78 Cr | 51.45 Cr | 50.32 Cr | 50.05 Cr | — |
| Depreciation | 55.78 Cr | 51.45 Cr | 50.26 Cr | 50.01 Cr | — |
| Gain Loss On Investment Securities | -0.31 Cr | 0.18 Cr | -0.11 Cr | -1.60 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.25 Cr | -1.83 Cr | -1.31 Cr | 1.21 Cr | — |
| Net Income From Continuing Operations | 211.77 Cr | 235.53 Cr | 224.18 Cr | 269.96 Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 0.76 Cr | 0.00 | — |
| Common Stock Issuance | — | 0.00 | 0.76 Cr | 0.00 | — |
| Net Other Investing Changes | — | -0.01 Cr | 1000.00 | -0.01 Cr | -1000.00 |
| Amortization Cash Flow | — | 0.40 Cr | 0.06 Cr | 0.04 Cr | 1.18 Cr |
| Gain Loss On Sale Of PPE | — | — | -0.11 Cr | -0.02 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Aarti Drugs Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.